{"id":"yl202","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SGLT2 is a protein responsible for glucose reabsorption in the kidneys. By inhibiting SGLT2, YL202 reduces glucose reabsorption, leading to increased glucose excretion in the urine and decreased blood glucose levels.","oneSentence":"YL202 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:18.213Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07461454","phase":"PHASE3","title":"YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2026-03-10","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":376},{"nctId":"NCT07202364","phase":"PHASE2","title":"A Study of YL202 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2025-08-04","conditions":"Non Small Cell Lung Cancer, Colorectal Cancer, Cervical Cancer","enrollment":100},{"nctId":"NCT07416994","phase":"PHASE3","title":"Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2026-03-06","conditions":"Non-Small Cell Lung Cancer","enrollment":440},{"nctId":"NCT06107686","phase":"PHASE2","title":"A Study of YL202 in Selected Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2023-12-15","conditions":"NSCLC, Breast Cancer, HNSCC","enrollment":200},{"nctId":"NCT07169994","phase":"PHASE1, PHASE2","title":"A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2025-09-02","conditions":"Advanced Solid Tumors, Breast Cancer, Non Small Cell Lung Cancer","enrollment":414},{"nctId":"NCT05653752","phase":"PHASE1","title":"A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2022-12-20","conditions":"Non Small Cell Lung Cancer, Breast Cancer","enrollment":80},{"nctId":"NCT06439771","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC","status":"RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2024-04-23","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"YL202","genericName":"YL202","companyName":"MediLink Therapeutics (Suzhou) Co., Ltd.","companyId":"medilink-therapeutics-suzhou-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"YL202 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}